-
INZY Dashboard
- Financials
- Filings
-
Holdings
-
Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Inozyme Pharma (INZY)
Company Profile
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 24.89 mm | 24.89 mm | 24.89 mm | 24.89 mm | 24.89 mm | 24.89 mm |
Cash burn (monthly) | (no burn) | 1.86 mm | 8.28 mm | 8.31 mm | 8.18 mm | 7.60 mm |
Cash used (since last report) | n/a | 8.12 mm | 36.18 mm | 36.27 mm | 35.71 mm | 33.19 mm |
Cash remaining | n/a | 16.76 mm | -11.29 mm | -11.39 mm | -10.82 mm | -8.31 mm |
Runway (months of cash) | n/a | 9.0 | -1.4 | -1.4 | -1.3 | -1.1 |
13F holders | Current |
---|---|
Total holders | 92 |
Opened positions | 10 |
Closed positions | 12 |
Increased positions | 36 |
Reduced positions | 21 |
13F shares | Current |
---|---|
Total value | 281.50 bn |
Total shares | 67.71 mm |
Total puts | 5.80 k |
Total calls | 3.70 k |
Total put/call ratio | 1.6 |
Largest owners | Shares | Value |
---|---|---|
Adage Capital Partners GP, L.L.C. | 5.67 mm | $29.67 bn |
Pivotal bioVenture Partners Fund I | 4.49 mm | $26.57 mm |
Pivotal bioVenture Partners Investment Advisor | 4.49 mm | $23.51 bn |
Sofinnova Investments | 4.28 mm | $22.39 bn |
Longitude Capital Partners III | 4.17 mm | $20.96 mm |
Eventide Asset Managment | 4.13 mm | $21.62 bn |
Rock Springs Capital Management | 3.80 mm | $19.89 bn |
BlackRock | 3.49 mm | $18.26 bn |
Samlyn Capital | 3.26 mm | $17.05 bn |
Affinity Asset Advisors | 2.82 mm | $14.76 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
3 Oct 24 | Erik Harris | Stock Option Common Stock | Grant | Acquire A | No | No | 5.06 | 56,000 | 283.36 k | 56,000 |
30 Sep 24 | Matthew Winton | Common Stock | Grant | Acquire A | No | No | 4.45 | 1,710 | 7.61 k | 4,898 |
30 Sep 24 | Treco Douglas A | Common Stock | Grant | Acquire A | No | No | 4.45 | 1,710 | 7.61 k | 22,375 |
18 Jun 24 | Edwards Martin | Stock Option Common Stock | Grant | Acquire A | No | No | 4.4 | 28,000 | 123.20 k | 28,000 |